Dual function proteins for treating metabolic disorders
WO2014151630A2
Compounds and compositions for the treatment of parasitic diseases
WO2014151729A1
Compounds and compositions for the treatment of parasitic diseases
UY35368A
PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF ARTICULAR DAMAGE
WO2014138485A1
Ex vivo production of platelets from hematopoietic stem cells and the product thereof
WO2014124258A2
Specific sites for modifying antibodies to make immunoconjugates
WO2014078813A1
Compounds and compositions for the treatment of parasitic diseases
WO2014052619A1
Piperidine derivatives and compositions as modulators of gpr119 activity
WO2014028748A1
Interleukin 2 antibodies and antibody complexes
EP2861578A1
Compounds and compositions for modulating egfr activity
TN2013000241A1
Compositions and methods for modulating fxr
CN104520291A
Compounds and compositions for modulating egfr activity
TN2013000211A1
Methods of treating fgf 21- associated disorders
AU2013203936A1
Compounds that expand hematopoietic stem cells
AU2013203167A1
Adsorption of immunopotentiators to insoluble metal salts
AU2013202463A1
Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
AU2013226323A1
Cancer patient selection for administration of Wnt signaling inhibitors using RNF43 mutation status
KR20140105433A
Compounds and compositions as pdgfr kinase inhibitors
KR20140071384A
Compounds and compositions as c-kit kinase inhibitors
EP2751103A1
Compounds and compositions as c-kit kinase inhibitors
